The global hypopituitarism diagnostics market is expected to garner a market value of USD 250 Million in 2023 and is expected to accumulate a market value of USD 447.41 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Hypopituitarism Diagnostics registered a CAGR of 4% in the historical period 2017 to 2022.
Hypopituitarism happens when your pituitary gland is not active enough, resulting in the gland not making enough hormones. The major factors attributing to the growth of the market are pituitary tumors, Infections or inflammatory diseases, and the increasing prevalence of hormonal problems. Furthermore, the increasing number of people suffering from autoimmune diseases and genetic diseases are also the major factors that help in driving the growth of the market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 250 Million |
| Anticipated Forecast Value (2033) | USD 447.41 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Hypopituitarism Diagnostics reflected a value of 4% during the historical period, 2018 to 2022. Urban lifestyles and degrading food habits are expected to increase the demand for hypopituitarism diagnostics and treatment facilities.
Due to the hectic life patterns of the citizens working in cities, there has been an observed increase in stress and sleeplessness. These challenges are emerging as the main factor for the deteriorating health in the urban population by disrupting the hormonal balance in the human body. Medication growth hormones are the appropriate short-term remedies for such situations that are getting more and more popular among youngsters and old age people equally around the world.
In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of the Hypopituitarism Diagnostics Market is fuelling the market growth. Thus, the market for hypopituitarism diagnostics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Strong Relation Between Hypopituitarism and Growth Hormone Deficiency to push the market growth
The human growth hormone helps to stimulate regeneration, reproduction, and growth. Rising use of growth hormones and awareness about growth hormones, which help in the management of growth hormone deficiency disorders, are boosting the market growth. The strong connection between growth hormone deficiency and Hypopituitarism Diagnostics disease is one of the biggest drivers of the market.
According to a research article by Mohamed Hamdy Elkarow et al., published in the Frontiers in Endocrinology Journal in November 2020, patients with decreased growth hormone secretion constitute a risk factor for COVID-19 severity, which requires attention toward preventive measures in susceptible individuals. Though growth hormone deficiency among humans is a rare condition with a chance of 0.001% on a global scale, it creates an immense opportunity for business ventures in the market.
Furthermore, most companies are investing in Research and Development
to develop a growth hormone that has fewer side effects and will be a long-acting hormonal therapy. In addition, the rapid development of new novel recombinant human growth hormones is expected to drive the hypopituitarism market over the forecast period. Considering these factors, the market is projected to show considerable growth through 2033.
Increased Prevalence of Hypopituitarism in Pregnant Women to Bolster the Treatments’ Demand
According to an analysis conducted by National Center for Biotechnology Information, hypopituitarism is associated with an increased risk of pregnancy complications, such as abortion, anemia, pregnancy-induced hypertension, placental abruption, premature birth, and postpartum hemorrhage.
Women with hypopituitarism often need assisted reproductive treatment, with pregnancy rates ranging from 47% to 100%. In patients achieving pregnancy, the live birth rate ranged from 61% to 100%. While glucocorticoids, levothyroxine, and desmopressin are safely prescribed during pregnancy, growth hormone treatment regimens vary significantly between countries, and several publications support a positive effect in women seeking fertility.
Considering the above-mentioned insights, replacement of deficient hormones remains the main treatment modality for hypopituitarism, and the order of treatment is a glucocorticoid, thyroid hormone, sex hormone, and growth hormone. In general, thyroid hormone replacement should be initiated two weeks after glucocorticoid replacement, and it is advisable, to begin with, a low dosage to prevent an Addisonian crisis.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Hypopituitarism Diagnostics, less awareness of Hypopituitarism Diagnostics disease, and insubstantial treatment options are hampering the market growth.
Improvement in healthcare spending propelling the growth of Hypopituitarism Diagnostics in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Hypopituitarism Diagnostics Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the treatment market worldwide.
Technological Advancements Shaping Landscape for Hypopituitarism Diagnostics in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. As per the American Academy of Pediatrics, growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the USA.
In addition to this, increasing awareness about growth hormone deficiencies and treatment is expected to boost market growth. Every year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) celebrates Children’s Growth Awareness Day to spread awareness about the early diagnosis and treatment of growth hormone disorders.
Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospitals to take the lead and drive market growth
The application segment has been divided into hospitals, home care, and clinics. According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the hypopituitarism diagnostics facilitates the growth of this segment.
Key start-up players in the Hypopituitarism Diagnostics Market are-
Eli is a Canadian FemTech start-up developing an at-home device that can capture daily hormone fluctuations from saliva and an app to provide insights tailored to each user’s unique profile. Hormones are core to women’s reproductive and general health, yet they remain a black box. Eli unlocks this box and puts women’s daily hormonal data in women’s hands. The company develops an at-home device that captures hormone fluctuations in saliva and an app that gives women the information they want to own their health decisions, every day and across life.
DiogenX is a start-up from France developing pancreatic beta-cell modulators for the treatment of type-1 and type-2 diabetes. The startup’s lead candidate is a recombinant protein that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of lifestyle and disease management. DiogenX targets beta-cell failure by stimulating functional beta-cell recovery in diabetic patients. This method further helps rebalance glucose or insulin homeostasis.
Inne is a German FemTech Startup. The Founder + CEO of Inne, Eirini Rapti, created the Hormonal Health Startup motivated by her own desire to use natural contraception but realized that traditional natural fertility methods were almost impossible to use reliably in real life. She was determined to find a way of leveraging technology to enable all women to have a greater understanding of their bodies and take control of their contraceptive choices so that they could make the most of their careers and relationships. Eirini set about developing a saliva biosensor device that enables women to identify and predict the fertile phase in their natural cycle.
Key players in the Hypopituitarism Diagnostics Market are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific.
In January 2022,Pfizer Inc. and OPKO Health, Inc. announced that the USA Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency (GHD) in pediatric patients. Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 250 Million |
| Market Value in 2033 | USD 447.41 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Test Type, End-Users, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Abbott Laboratories; Becton, Dickinson, and Company; BioMerieux; Bio-Rad Laboratories Inc.; Danaher Corporation; Siemens AG; Hologic Inc.; Qiagen NV; F. Hoffmann-La Roche AG; Thermo Fisher Scientific |
| Customization | Available Upon Request |
The growing prevalence of hypopituitarism driving the growth in the China region.
The availability of reimbursements for diagnostic tests is driving the growth in Germany.
The booming healthcare sector has necessitated hypopituitarism diagnostics services.
The United States held 28% of the global market share in 2022.
High cost and insubstantial treatment options.
1. Executive Summary | Hypopituitarism Diagnostics Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type 5.1. Hormone Stimulation Tests 5.2. MRI or CT Scan 5.3. Visual Field Check 5.4. Insulin Tolerance Test 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 6.1. Hospitals 6.2. Specialty Clinics 6.3. Academic Research Institutes 6.4. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Abbott Laboratories 15.2. Becton, Dickinson and Company 15.3. BioMerieux 15.4. Bio-Rad Laboratories Inc. 15.5. Danaher Corporation 15.6. Siemens AG 15.7. Hologic Inc. 15.8. Qiagen NV 15.9. F. Hoffmann-La Roche AG 15.10. Thermo Fisher Scientific 16. Assumptions & Acronyms Used 17. Research Methodology
Healthcare
January 2023
REP-GB-16359
297 pages
Explore Healthcare Insights
View Reports
Hypopituitarism Diagnostics Market
